Magill Medical Submits IPO Prospectus: Pioneering Global Airway Management with SafeLM® Visual Laryngeal Mask
As the saying goes, “Surgeons treat diseases, while anesthesiologists save lives.” This is indeed the case. When patients undergo general anesthesia, they are unable to breathe spontaneously. Anesthesiologists must establish an airway to ensure oxygenation, a process known as “airway management.” This represents the highest-risk phase of surgical anesthesia and is where adverse events are most likely to occur.
Laryngeal mask airways (LMAs) are a commonly used ventilation device in airway management. Due to advantages such as ease of use, minimal trauma to the pharynx and airway, and reduced anesthetic requirements, they have been increasingly widely adopted in clinical airway management. Global annual usage exceeds 100 million units. Compared with traditional endotracheal intubation, LMAs cause less hemodynamic fluctuation, have a lower incidence of complications, and facilitate faster postoperative recovery; consequently, their usage has surpassed that of endotracheal tubes in European and American markets.
However, the use of conventional laryngeal mask airways (LMAs) for “blind insertion” relies heavily on the operator’s experience. Improper alignment during insertion may cause soft tissue abrasions in the pharynx, cartilage dislocation, and laryngeal edema. After insertion, the inability to visually confirm cuff positioning poses risks such as misalignment, displacement, air leakage, and regurgitation with aspiration, which can be life-threatening in severe cases.
Addressing the aforementioned unmet clinical pain points,Changsha Maigeer Medical Technology(hereinafter referred to as“Maiji Medical”) After years of research and development, launchedSafeLM®Visualized Laryngeal Mask Airway System, through a patented optical path design, pioneeringly breaksBreaking the limitation of the rotation angle of the camera inside the laryngeal mask airway, therebyThe observation success rate has increased significantly to nearly 100%.
Majier Medical, specializing in the R&D and manufacturing of innovative medical devices. The company is located in the Oufuan Industrial Park, Changsha High-Tech Zone, with established6,000 m² R&D Center and GMP Workshop. Since its establishment in 2018, the company has filed more than ten Chinese and international invention patents, which have been approvedThree Domestic Medical Device Registration Certificates，Approved by the U.S. FDATwo EU CE certifications are currently under application.
Behind the corporate name “Magill Medical” lies an interesting story. Ivan Magill was a legendary British anesthesiologist in the 19th century who invented or redesigned endotracheal tubes, anesthesia machines, and other medical devices commonly used in modern anesthesia around 1920, significantly advancing the field of anesthesiology. In recognition of his outstanding contributions, Dr. Magill received numerous honors worldwide and was even knighted by the British Royal Family.
“We chose ‘Magill’ as our company name to honor Dr. Magill, while also reflecting our original aspiration to develop innovative medical devices that benefit patients worldwide,” said Dr. Li Daqing, founder of Magill Medical.
In fact, the global industry has been striving to develop video laryngeal mask products. Products already available internationally include Teleflex’s LMA CTrach™ from the United States and Medcom’s Flow TotalTrack VLM™ from Spain, while relevant companies in China have also launched similar products.
According to Niu Wei, co-founder of Magill Medical, due to technological limitations, these products all feature cameras fixed at a specific angle. Given the structural complexity and individual variability of human pharyngeal tissues, such video laryngoscopes with a fixed viewing angle can only fully visualize the glottis in approximately 35% of patients. Magill Medical has undertaken technological R&D and innovative structural design, “achieving 100% glottic visualization across the entire patient population.”Completely surpasses similar foreign products.”。
According to Niu Wei, anesthesiology experts both in China and abroad unanimously agree that visualization technology represents the inevitable trend in airway management. Therefore, the SafeLM® visual laryngeal mask is poised to gradually replace traditional blind-insertion laryngeal masks and a significant proportion of endotracheal intubations, indicating substantial market potential.
As Magill Medical's flagship product, SafeLM®The visualized laryngeal mask system consists of a video bronchoscope and a disposable, angle-adjustable, visible laryngeal mask. It provides full-process visual guidance during insertion into the patient’s trachea, ensuring accurate positioning, effectively reducing the risk of airway injury, and eliminating epiglottic interference, thereby offering greater safety and reliability compared to blind intubation.
SafeLM®Visualized Laryngeal Mask Airway System
SafeLM®The main shaft of the visualized laryngeal mask is made of PVC, providing sufficient support strength to facilitate insertion and position adjustment, thereby reducing the risk of intraoperative displacement. The cuff is made of silicone, offering softness, comfort, and excellent sealing performance. Additionally, this product features the following advantages:
Easy to assemble and convenient to use.SafeLM®The visual laryngeal mask is easy to assemble; simply insert the video stylet into the imaging channel port of the mask before use. The operator adjusts the camera’s field of view by rotating the angle-adjustment knob. The display screen provides a clear, glare-free real-time visualization of the insertion process.
Observation range exceeds 180 degrees, providing a clear and wide surgical field.Traditional visual laryngeal masks have a limited field of view due to technical constraints and fixed cameras, failing to meet clinical needs. SafeLM®The camera angle of the visual laryngeal mask airway is adjustable, a feature protected by an international invention patent. With a field of view exceeding 180 degrees, it allows for timely adjustment in case of misalignment. This design not only prevents obstruction by tissues such as the epiglottis but also enables visualization of the cuff’s peripheral seal and any secretions within the cuff, thereby ensuring safe ventilation. Particularly during emergency resuscitation or difficult intubation scenarios, it facilitates simultaneous ventilation and intubation, thus improving the success rate of ventilation.
Safe and hygienic, minimizing the risk of cross-infection.SafeLM®The visual channel at the distal end of the video laryngeal mask airway is sealed, providing excellent airtightness with a maximum sealing pressure of up to 35–40 cmH2O, offering stability far superior to that of conventional laryngeal mask airways. During use, the laryngoscope does not come into direct contact with the patient, thereby eliminating the risk of cross-infection between healthcare providers and patients.
Automatic loop recording of surgical videos upon startup, safeguarding medical safety.Capable of storing approximately 8 hours of video footage; the USB cable facilitates easy video export, serving as a learning resource for junior physicians and providing evidentiary reference in the event of medical malpractice disputes.
Additionally, SafeLM®Visualized Laryngeal Mask AirwayComplete range of specifications; suitable for both infants and adults.Wide range of applicable populations and diverse usage scenarios. Based on these advantages, Maijier SafeLM®The Visual Laryngeal Mask Airway System Has Been Successfully SelectedMedical Emergency Equipment for the 2022 Beijing Winter Olympics, stationed at Winter Olympics venues to undertake medical emergency support tasks.
Professor Van Zundert, Head of the Department of Anaesthesiology and Intensive Care at The University of Queensland, AustraliaReviewed the product, stating: “Maijier SafeLM®"The visual laryngeal mask system is currently the only true visual laryngeal mask, and it is also the world's only third-generation laryngeal mask!"(Editor’s Note: First-generation laryngeal mask airways (LMAs) are single-lumen devices intended only for short-term procedures, carrying a risk of regurgitation and aspiration. Second-generation LMAs are primarily double-lumen devices incorporating a gastric access port, thereby reducing the risk of regurgitation and aspiration. Third-generation LMAs refer to devices that enable true visualization.)
According to Niu Wei, anesthesiology experts both in China and abroad unanimously agree that visualization technology is the inevitable trend in airway management. Therefore, the SafeLM® video laryngeal mask is poised to gradually replace traditional blind-insertion laryngeal masks and a majority of endotracheal intubations, indicating immense market potential.
While Maigeer Medical’s product portfolio may not be as dazzlingly extensive as those of some competitors, the company retains full in-house control over core technologies and mass-production expertise for every product—from concept to commercialization, and from minute details to underlying technology. This achievement is underpinned by the rich experience and close collaboration of its two founders.
Dr. Li Daqing, Founder and CEO of Maiji Medical
Dr. Li Daqing, Founder and CEO of Maiji Medical,Ph.D. in Physics, with nearly 30 years of deep expertise in the medical device and electronics industries. He participated in the development of China’s first domestically produced magnetic resonance imaging (MRI) system. Later, he joined Huawei to engage in technical research and development of communication electronic products, holding senior management positions. In 2005, Dr. Li Daqing founded Changsha Jianyuan Medical Technology Co., Ltd., developing and marketing infusion pumps, syringe pumps, enteral feeding pumps, and other products. Within a few years, the company grew from scratch to become a leading Chinese manufacturer of infusion pumps, exporting to more than 50 countries. In 2013, Changsha Jianyuan was acquired by the Germany-based Fresenius Group, a Fortune Global 500 company. Dr. Li joined Fresenius as Vice President, overseeing R&D and production management. In 2018, Dr. Li embarked on his second entrepreneurial venture by establishing Changsha Maijier Medical Technology Co., Ltd., focusing on the development of innovative medical devices.
Niu Wei, Co-Founder and Vice President of Business Development
Niu Wei, Co-founder and Vice President of Business Development,With over twenty years of marketing and management experience in the pharmaceutical and medical device industries, Niu Wei has held sales, marketing, and leadership positions at Roche Pharmaceuticals (Switzerland), Karl Storz (Germany), Boston Scientific (USA), and Hospira (USA). He has successfully introduced numerous advanced foreign medical devices to the Chinese market, accumulating extensive expertise in marketing and sales. Throughout his career, he has participated in early-stage R&D projects for innovative products, business development (BD) initiatives, strategic collaborations, as well as corporate investment and M&A activities. He possesses comprehensive knowledge of the end-to-end commercialization process for innovative medical products and offers unique, profound insights into industry trends and market dynamics.
The two founders of Maiji Medical represent a classic entrepreneurial combination of “tech visionary + commercialization expert.” Each excels in their respective domain, with their professional expertise and commercialization capabilities complementing and reinforcing one another.
Currently, the entire team at Maiji Medical consists of over 50 members, includingR&D Personnel Account for One-Third。
Magir Medical’s business model is not complex, with“Patented Equipment + Dedicated Consumables”as the mainstay, with a clear profit model.
In terms of corporate strategy, Maigeer Medical adheres to the principle of “meeting clinical needs, targeting the global market, and persisting in independent innovation.”
In terms of product strategy, Maigeer MedicalWe remain committed to addressing genuine clinical needs, focusing exclusively on products powered by our proprietary core patented technologies and delivering globally leading performance.Currently, SafeLM®The visualized laryngeal mask airway system has been recognized by top-tier hospitals in China and the United States, achieving strong market reception.
While solidifying its core business, Majier Medical is also meticulously addressing clinical pain points and actively developing new products to expand the boundaries of innovation. The company’s R&D team has found that in recent years, adverse events related to infusion pumps have remained persistently high in China’s medical device adverse event reports.
According to Dr. Li Daqing, founder of Maiji Medical, most infusion pumps currently used in China operate on the peristaltic principle, working by sequentially compressing PVC infusion tubing with pump cams. This method fails to ensure precise infusion control and poses safety risks. In contrast, infusion pumps in Europe and the United States mostly employ specialized silicone infusion sets or clamps, which enhance infusion accuracy. In light of this, Maiji Medical has combined this approach with its patented valve-based mechanism to launch a high-precision, multifunctional, portable infusion pump, significantly improving both the accuracy and safety of infusion therapy.
Majir Medical High-Precision Multifunctional Portable Infusion Pump
Magir Medical High-Precision Multifunctional Portable Infusion Pump: Featuring the world’s highest precision among similar products, large capacity, portability, intelligent programmability, vascular protection (automatically releasing pressure to protect blood vessels during infusion obstruction), and 5G remote management capabilities. Suitable for various scenarios including outpatient wards, home care, emergency response, and battlefield use.
Currently, this new portable infusion pump has completed CE certification by TÜV Rheinland in Germany. The test report indicates that its key performance metrics, such as infusion control accuracy and safety features, are far ahead of other infusion pump products worldwide.
“We started with anesthesia and infusion products, areas we are familiar with, but we are not confined to these two fields,” introduced Dr. Li Daqing. In terms of product development, Maijier Medical is leveraging its team’s technical strengths (such as mechatronics and algorithms) to develop innovative medical device products covering multiple therapeutic areas, and has recently filed multiple invention patent applications.Innovative patented products in fields such as oncology and surgery are expected to be rolled out successively over the next 1–2 years.
In terms of market strategy, Maiji'er MedTherapeutics emphasizes academic promotion, and engage in academic collaborations with leading medical institutions both domestically and internationally to demonstrate the clinical value of products through clinical data. Meanwhile, collaborate withDomestic and International Distribution Channel Cooperation, expanding the horizontal and vertical coverage of the market. After more than a year of effort, the company's products have been implementedPeking University Third Hospital, The First Affiliated Hospital of Zhengzhou University, and other leading domestic Grade-A tertiary hospitals, will undertake more initiatives in the coming yearMarket coverage of tertiary and secondary hospitals.
Meanwhile, the company is actively pursuing approvals from foreign regulatory authorities to establish a presence in overseas markets. Its core product, SafeLM®Visual Laryngeal Mask Airway SystemFDA Approved, and inCleveland Clinic, Texas Medical Center...among other top-tier hospitals, with positive feedback. Maiji Medical will bring SafeLM®The visual laryngeal mask airway system will be showcased at the American Society of Anesthesiologists (ASA) Annual Meeting, held in Orlando on October 22 this year, to present Chinese innovative products to more American physicians. Furthermore, this productCE certification is expected to be obtained by the end of 2022.At that time, Majier Medical will use this as an entry point.European Hospital Market.
“We began commercialization last year and have already generated sales revenue, with overall momentum remaining positive,” Niu Wei revealed. The company initially relied entirely on the founders’ own capital investment; as it entered a phase of rapid growth,Seeking capital injectionto accelerate the commercialization of the company's domestic and international markets, as well as the subsequent development of new products.